Tools
Primary Intraocular Lymphoma
Introduction
Primary intraocular lymphoma (PIOL) is a rare ocular malignancy and is considered as a subset of primary central nervous system lymphoma (PCNSL) with ocular involvement.[1] It is an extranodal non-Hodgkin, diffuse large B cell lymphoma. It was earlier known as “malignant lymphoma of the uveal tract” and “reticulum cell sarcoma,” which was misleading, and hence, these names went out of vogue. As vitreoretinal manifestations predominate, it is also known as primary vitreoretinal lymphoma (PVRL) or primary central nervous system lymphoma-ocular or ophthalmic variant (PCNSL-O) in literature.[2][3][4][5]
Secondary intraocular lymphoma arises outside the central nervous system or eye and later metastasizes to the eye.[6] The lymphoma cells here predominantly involve the uveal tissue.[7] Primary uveal lymphoma is a less common entity involving B cell infiltration of the uveal tract and belongs to the extranodal marginal zone or mucosa-associated lymphoid tissue lymphoma.[8] It is distinct from PIOL of diffuse large B cells and carries a better prognosis.[9]
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
The etiopathogenesis of primary intraocular lymphoma is still not well understood.
Chemokine theory – B cell chemokines such as B-lymphocyte chemoattractant (BLC) and stromal cell-derived factor-1 (SDF-1) present in retinal pigment epithelium (RPE) attract lymphoma cells from the choroidal circulation to RPE.[10]
Infection theory – Infectious agents are known to cause lymphocyte proliferation which later turns into clonal proliferation. Epstein-Barr virus (EBV) infection of the B lymphocytes results in uncontrolled proliferation of the lymphocytes in the absence of T- suppressor lymphocytes in immunodeficiency states such as AIDS (acquired immunodeficiency syndrome).[11] This is supported by the invariable presence of EBV in AIDS patients with PCNSL. However, a similar association has not been noted in immunocompetent individuals with PIOL.[12] Similarly, Toxoplasma gondii DNA has been detected in B cell lymphoma cells of PIOL.[13]
Epidemiology
The exact epidemiology of PIOL is not known. Most of the available data relates to a larger group of primary central nervous system lymphoma. PCNSL accounts for 1 to 2% of all extranodal lymphomas and 3 to 5% of primary CNS (central nervous system) tumors.[14] It is more commonly seen in immunocompromised individuals.[15] However, with the advent of highly active antiretroviral therapy (HAART), its incidence among immunocompromised individuals has come down.[16]
Primary intraocular lymphoma usually occurs in adults from the third to eighth decade of life, with a mean age of presentation in the fifth and sixth decades of life.[17] Few cases have been reported in extremes of age group. In Immunocompromised individuals, PIOL occurs in younger individuals.[18] There are no known racial or ethnic associations. Women are more commonly affected than men in the ratio of 2 to 1.[19]
Pathophysiology
Most primary intraocular lymphomas originate from B lymphocytes (late germinal or post germinal center).[20] Very rarely, PIOLs may have T cell origin.[21] Primary CNS lymphoma originates from late germinal or post-germinal center lymphoid cells with neurotrophic localization to the central nervous system. The trafficking of lymphoma cells from brain to eye and vice versa involves direct invasion of the optic nerve, presence of common venous drainage, or common integrin expression.[22]
History and Physical
Primary intraocular lymphoma is a great masquerader and can mimic nonspecific uveitis. The delay between the onset of symptoms (ocular or CNS) and a positive diagnosis usually varies from 4 to 40 months.[23] About ¼th of patients with PCNSL will have concomitant vitreoretinal lymphoma at the time of diagnosis.[24] Conversely, 56 to 90% of individuals with vitreoretinal lymphoma will develop CNS involvement over a follow-up period of 8 to 29 months.[25] At the initial presentation of PIOL, about 16 to 34% of patients tend to have central nervous system involvement.[26]
Ophthalmic Findings
The most common symptom is a painless blurring of vision or a complaint of floaters. The disease is bilateral in 80% of the individuals and is asymmetric in presentation.[27] Anterior segment findings include cells in the anterior chamber, keratic precipitates, infiltration of iris or angle, and rarely pseudohypopyon. Posterior segment findings can mimic choroiditis or vasculitis and include vitritis, which is surprisingly responsive to topical and oral steroids initially. The vitreous cells may form clumps, sheets, or strands leading to media haze. The cells in PIOL are larger than inflammatory cells. These cells do not cluster with reactive cells. They are arranged along vitreous fibrils in the form of linear opacities giving rise to the "aurora borealis "appearance of vitreous or a "string of pearls" appearance, which includes fine fibrils connecting bunches of inflammatory material.[28][29]
Creamy lesions with yellowish-orange subretinal or sub-RPE infiltrate may be seen, leading to "leopard skin pigmentation" over the lesions.[30] This may be associated with exudative retinal detachment. Spontaneous resolution may lead to RPE atrophy and subretinal fibrosis.[31] Posterior synechiae formation and scleral inflammation are not frequently seen in PIOL.[17] In contrast to other uveitic conditions with a similar degree of inflammation, cystoid macular edema is often absent, and vision is comparatively preserved.[32] Orbital involvement in PIOL is exceptionally rare and helps in differentiating it from simulating lesions.[33]
Central Nervous System (CNS) Findings
The new onset of seizures indicates CNS involvement in a case of PIOL.[34] Symptoms can be either focal or diffuse. The most common focal symptoms include hemiparesis (51%) and cerebellar ataxia (23 %).[24] Involvement of the frontal lobe leads to behavioral changes and cognitive impairment.[35]
Evaluation
- Imaging
- Biopsy & analysis
- Blood tests
| Imaging |
|
| Biopsy and analysis |
|
| Blood tests | To rule out common uveitic conditions and other masquerades |
I. Imaging
- Optical coherence tomography (OCT): It is helpful to demonstrate or analyze lesions at the posterior pole. Findings include nodular hyperreflective lesions in the retinal pigment epithelial layer corresponding to subretinal and sub-retinal pigment epithelium (RPE) lymphoma deposits (Figure 1).[36] It is also useful to confirm the absence of cystoid macular edema.[32] The images are usually difficult to capture as the ocular media is usually hazy due to vitreous involvement.
- Fundus Fluorescein angiography (FFA): Findings in FFA include small hypofluorescent lesions in the early and late phase corresponding to infiltrates masking the choroidal fluorescence, with late staining at the level of RPE in another series.[37] other findings include punctate hyperfluorescent window defects, vasculitis, and very rarely petaloid leak at the macula.[32][17]
- Indocyanine green angiography (ICGA): It shows small hypofluorescent lesions in the early phase, which become less apparent in late phases. The hypofluorescent lesions are more numerous in FFA compared to ICGA.[32]
- Fundus Autofluorescence (FAF): Sub-RPE pigment clumps that give rise to "leopard spotting" appearance are hyperautofluorescent, whereas white lesions above the RPE are hypoautofluorescent.[21] Granularity on FAF is noted in cases with active lymphoma.[38]
- Ocular ultrasound: There are no definitive findings of PIOL on ocular ultrasonography. The most common ultrasound findings in the case of PIOL include vitreous echoes, elevated chorioretinal lesions, and retinal detachment.[39]
- Neuroimaging: Computed tomography (CT) and magnetic resonance imaging (MRI) imaging of the brain show unifocal or multifocal periventricular, homogenously contrast-enhancing lesions.[40][41] In CT imaging, the lesions are isodense or hyperdense, while in MRI, lesions are hyperintense on T1 imaging and iso-hyperintense on T2 imaging.[42]
II. Biopsy and Analysis
The definitive diagnosis depends on the demonstration of the malignant lymphoma cells in the ocular specimens (vitreous, aqueous, chorioretinal biopsy) or the cerebrospinal fluid (CSF).[4] Typically lymphoma cells are present between RPE and Bruch's membrane; however, the lymphoma cells invade the vitreous, and hence vitreous sampling also helps in evaluation. A chorioretinal biopsy is often indicated if there is an absence of anterior chamber or vitreous cavity inflammation, the presence of a fovea threatening lesion that is non-responsive to treatment, infection with equivocal results on prior testing, or in cases with a strong suspicion of neoplasm.[43] Multiple biopsies may sometimes be needed to reach a definitive pathological diagnosis. Uveal biopsies are often nondiagnostic.
Ocular Biopsy
Technique: Techniques of ocular biopsy include fine-needle aspiration of vitreous via pars plana (21G to 25G), pars plana vitrectomy, transscleral biopsy for subretinal lesions, anterior chamber tap, and enucleation. Vitrectomy has added advantage of clearing vitreous debris, maximizing sample collection, and access to subretinal space, although there is a risk of extension of lymphoma through the sclerotomy site to peribulbar space.[44][45] In cases of a painful blind eye, a diagnostic enucleation may be performed.[46]
Techniques to increase the diagnostic yield include
- Any corticosteroid use should be discontinued for at least two weeks before the biopsy.[47]
- Precautions during vitrectomy include the use of large-bore cutters and a low cut rate to reduce the shearing of cells.
- Collect undiluted fresh vitreous with infusion off.
- Since lymphoma cells undergo morphological degeneration within 60 minutes, the sample should be transported to the laboratory quickly.
- Fixation of the sample in HOPE (HEPES-glutamic acid buffer-mediated Organic solvent Protection Effect) solution may increase the yield.[48]
Cerebrospinal Fluid (CSF) and Brain Biopsy
A lumbar puncture can be done to obtain CSF in cases with suspected PCNSL. In cases with a positive yield on CSF and if an intraocular lesion suspicious of PIOL is present, the need for ocular tissue biopsy is less important unless the intraocular process does not respond to the treatment initiated.[43] Stereotactic brain biopsy is done in patients with negative CSF cytology and suspicious brain lesions on imaging.[49]
Analysis
- Histopathology: Histopathological analysis reveals a monoclonal population of large B cells with scanty cytoplasm, high nuclear: cytoplasmic ratio, hypersegmented round, oval, or clover-shaped nuclei with coarse chromatin pattern, and prominent or multiple nucleoli (Figure 2).[26][45] Cytological evaluation has a high positive predictive value of 99 – 100% and a negative predictive value of 61 to 81%.[50][51] Challenges in histopathological analysis of specimens include the presence of a sparse number of cells, confounding features such as T lymphocytes, necrotic cells, and fibrin.[26]
- Immunohistochemistry and flow cytometry: The presence of a monoclonal population of a single immunophenotype supports the histopathological diagnosis. Most cases of PIOL are monoclonal B cell lymphomas and stain positively for B cell markers like CD19, CD20, CD 22, and germinal center markers such as BCL 6 and CD 10.[52][53] Reactive inflammatory cells tend to be T cells and express CD 3 and CD 5.[25] Hence in a rare case of T cell PIOL, the distinction between inflammation and tumor is mainly based on morphology and demonstration of monoclonality.[54]
- Cytokines: B cells secrete high amounts of interleukin (IL) IL-10, an immunosuppressive cytokine.[55][56] On the other hand, in uveitis, the vitreous is rich in IL-6, a pro-inflammatory cytokine.[56] Intravitreal IL-10: IL-6 ratio>1 has 75% sensitivity of distinguishing PIOL from uveitis.[57]
- Polymerase chain reaction (PCR): In cases of PIOL, monoclonality of the B cell population can be detected using framework regions (FR)- FR2, FR3, and complementarity determining regions 3 (CDR3) primers.[58] Monoclonality of rare T cell PIOL can be detected through T-cell receptor (TCR) gene rearrangements.[7]
Given the paucity of vitreous available for testing, the histopathological analysis gets precedence, and the supernatant sample can be sent for cytokine analysis.[56] The sample can then be sent for immunohistochemistry/flow cytometry and PCR analysis, depending on the available sample amount.
III. Blood tests: These are basically done to rule out infective causes of uveitis such as syphilis, tuberculosis, herpes, toxoplasmosis, HIV (human immunodeficiency virus) status; inflammatory disorders such as sarcoidosis, Vogt Koyanagi Harada disease, Behçet, and also to look at side-effects of systemic chemotherapy.
Treatment / Management
Treatment goals include controlling the local disease along with preventing CNS dissemination. Treatment modalities include intravitreal injections, chemotherapy, and radiotherapy, used alone or in combination. Chemotherapy is considered the first-line therapy for PCNSL.[59] International PCNSL collaborative group recommends systemic therapy for PIOL with CNS involvement and local therapy for disease localized to the eye.[28] Therapies commonly used in systemic lymphomas are not commonly successful in PCNSL and PIOL.(B3)
| Local Therapy | Intravitreal chemotherapy, Radiation, Vitrectomy |
| Systemic Therapy | Chemotherapy, Chemoradiation |
Local Therapy
Intravitreal Methotrexate (MTX)
Dose: 0.4 mg in 0.1 ml[60]
Indications:
- Unilateral/Bilateral PIOL
- In combination with systemic chemotherapy for PVRL with CNS involvement
- Relapsed PIOL
- Ocular relapse of PCNSL
The therapeutic dose of intravitreal MTX is maintained in the vitreous for five days.[61] The most common administration scheme of intravitreal methotrexate is twice weekly for four weeks in the induction phase, weekly for eight weeks in the consolidation phase, and monthly for another nine months in the maintenance phase with a total of 25 injections.[60] A mean of 6.4 injections was needed to reach remission, with 95% of cases receiving 13 injections or less.[60](B3)
The common complications of intravitreal MTX include cataracts, corneal epitheliopathy and maculopathy, limbal stem cell damage, optic atrophy, and sterile endophthalmitis.[53] An aqueous paracentesis should be done to avoid subconjunctival extravasation, which can lead to pain, irritation, and corneal epitheliopathy.[62]
Intravitreal Rituximab
Dose: 1 mg in 0.1 ml[63]
It is an anti-CD20 monoclonal antibody, given as an intravitreal injection. There is a lack of standardization of treatment schedules varying from a single injection to multiple injections at variable intervals.[64] It is usually given as four-weekly intervals.[64][65] The primary response is usually good, but subsequent relapses may require intravitreal methotrexate and radiation.[63] Complications related to intravitreal injection of rituximab include cataract formation, increased intraocular pressure, granulomatous anterior uveitis, vitreous hemorrhage, and retinal detachment.[64] (B2)
Radiation Therapy
External beam radiotherapy is given to patients with PIOL without CNS involvement.[28] Traditionally given in the dose of 54Gy, but due to increased risk of radiation retinopathy, the dose has been reduced to 35 to 40 Gy in approximately 15 fractions of 2Gy each, from opposed lateral beams to include both the eyes.[19][66] (B2)
Whole-brain radiotherapy is added with ocular radiotherapy in cases with CNS dissemination and who do not respond to systemic chemotherapy or cannot tolerate aggressive therapies.[66] High dose low fractionation CNS irradiation can cause neurotoxicity, which can present in the form of depression.[67] The ocular side effects of external beam radiotherapy include dermatitis, punctate keratopathy, radiation retinopathy, cataract, optic neuropathy, and dry eye syndrome.[6](B3)
Vitrectomy
In cases with significant cellular load, this can be considered as an adjunct therapy for debulking.[43] This is often combined with intravitreal chemotherapy.
Systemic Therapy
Chemotherapy
Chemotherapy is the mainstay of the treatment - usually used in combination with radiation therapy or can also be used alone as primary therapy. The main barrier to systemic chemotherapy is penetration via the blood-brain barrier and blood-ocular barrier. Methotrexate and Cytosine arabinoside penetrate the blood-ocular barrier and are commonly used.
Route – Intravenous, Intrathecal
Methotrexate (MTX)
High-dose methotrexate can penetrate the blood-brain barrier, with a complete response rate of 50 to 80%,[68] and is usually included in all chemotherapeutic regimens. It is given in the dose of 8 g/m^2 intravenously. In the induction phase, it is given every 14 days until complete response, every 14 days for two doses in the consolidation phase, and every 28 days for 11 months in the maintenance phase.[69] Intrathecal methotrexate is given in a dose of 12 mg or 6 mg by Ommaya reservoir administered once per cycle.[70](B3)
Systemic MTX can cause ocular complications like periorbital edema, increased lacrimation, photophobia, blepharitis, conjunctival hyperemia, and photophobia.[53] Intrathecal methotrexate plays a role in cases with PIOL with CNS involvement.[71](B3)
Cytosine Arabinoside (Ara-C)
Cytosine Arabinoside, also used as a chemotherapeutic agent, can penetrate the ocular blood barrier.[72] High-dose Cytosine arabinoside (Ara-C) is given in the dose of 2 to 3 g/m^2 for three months for six cycles.[73] Intrathecal cytarabine is given in a dosage of 100 mg once per cycle.[70] Ocular complications of Ara-C include ocular irritation, conjunctivitis, and keratitis. (B3)
Rituximab
Intravenous rituximab is usually given along with methotrexate in cases with relapse/ recurrences of PVRL in the dose of 375mg/sqm.[63][70]
Combination Chemotherapy
A combination of MTX and Ara-C was used in patients with both ocular and CNS disease by Valluri et al.[74] Both ocular and CNS disease resolved with remission of at least 24 months.[53] MATRix therapy, which is a combination of MTX, cytarabine, thiotepa, and rituximab, has been tried in patients < 70 years of age with good response.[75] It has shown a complete remission rate of 50% compared to groups treated with MTX and cytarabine, where remission rate was 23%, and the group treated with MTX, cytarabine, and rituximab, where remission rate was 30%.[75](B3)
Autologous stem cell transplantation is done in cases of refractory or recurrent PCNSL and PIOL after a course of intensive chemotherapy to rescue from systemic side effects of high-dose chemotherapy.[76]
Drugs Under Ongoing Trials
Pomalidomide
It's a thalidomide-based agent, usually used for systemic diffuse large B cell lymphoma with better penetration to CNS. It has been tried along with dexamethasone systemically for recurrent or refractory CNS and vitreoretinal lymphoma with promising results. The dose-escalation schedule of pomalidomide that followed was 3,5,7,10 mg orally daily for 21 days every 28 days and dexamethasone 40 mg every week.[77]
Ibrutinib
It is an orally administered agent with significant penetration of the blood ocular/CNS barrier.[70] It acts by inhibiting Bruton tyrosine kinase and HCK tyrosine kinase protein, both of which are upregulated by MYD88 L265P mutation.[53] The presence of this particular mutation is responsible for potential sensitivity to Ibrutinib. It has been tried in the dosage of 560 mg orally once daily for 28 days until disease progression, or unacceptable toxicity occurred.[78] It is usually reserved for patients with relapse or recurrences of PCNSL and PVRL. Ibrutinib with high-dose systemic steroids can lead to invasive fungal and pneumocystis infections.[79]
Lenalidomide plus Rituximab
Lenalidomide and rituximab combination has shown promising results in recurrent/ relapsing PCNSL.[80] The regimen includes eight 28-day cycles of induction phase (lenalidomide 20 mg/day, days 1 through 21 for cycle one followed by 25 mg/day, days 1 through 21 for subsequent cycles in combination with intravenous rituximab 375 mg/m^2 ), and twelve 28-day cycles of maintenance phase (lenalidomide alone in the dose of 10 mg/day, days 1 through 21).[80](B2)
Chemoradiation
Combining chemotherapy with radiation can be used as primary therapy or as salvage therapy in PIOL.[81] Intra-thecal chemotherapy can also be combined with radiation.[82] Multimodal therapy leads to better disease control with delayed cognitive neurotoxicity.[83] Rituximab and methotrexate-based systemic chemotherapy along with intravitreal methotrexate and low dose brain irradiation (23.4Gy) had shown disease-free survival of up to 25 months.[84](B3)
Differential Diagnosis
Diagnosis of PIOL is very challenging as various infectious and non-infectious diseases can mimic the clinical condition. Various differentials include
Inflammatory Diseases
- Posterior uveitis/panuveitis
- Intermediate uveitis[85]
- Sarcoidosis
- Vogt Koyanagi Harada disease
- Behçet disease
- Multifocal choroiditis[86]
- Multiple evanescent white dot syndrome
- Acute posterior multifocal placoid pigment epitheliopathy
- Birdshot choroidopathy
- Serpiginous chorioretinopathy
- Frosted branch angiitis
Infectious Diseases
- Tubercular uveitis
- Endophthalmitis[87]
- Syphilis[88]
- Toxoplasmosis[89]
- Acute retinal necrosis[90]
- Herpetic uveitis
Neoplasms
- Amelanotic melanoma
- Metastatic cancers
In a study, the most useful signs to differentiate lymphoma from simulating conditions listed above were – better vision, less anterior chamber flare, less posterior synechiae, and less optic disc swelling, retinal vasculitis, or disc involvement.[32]
Treatment Planning
The treatment plan for the management of PIOL is varied, and no common consensus is available. The protocol suggested by Pulido et al. for treatment has been discussed in the following figures (Figures 3, 4, and 5).[70]
Prognosis
PIOL with CNS involvement has a poor ocular prognosis due to the intrinsic aggressive nature of the disease. In PIOL, the mortality rate ranges from 9 to 81% in a follow-up period from 12 to 35 months.[26] According to Hormigo et al., the survival advantage if PIOL was diagnosed before CNS involvement was found to be 60 months versus 35 months if it was found later.[91]
The IELSG score used for PCNSL prognostication is valid only for PVRL with CNS involvement.[75] Primary CNS lymphoma has a poor five-year survival rate of 30%.[92] The median survival in patients with PCNSL, who are treated with radiotherapy alone or chemoradiation, can go up to 10 to 16 months.[93] With methotrexate-based chemotherapy or ifosfamide or trofosfamide, the medial survival rate can go up to 30 months.[93][94]
In a study by Grimm et al., the patients after receiving a mix of therapies had a median survival of 31 months and median progression-free survival of 18 months, with ocular therapy causing no improvement in chances of survival.[95]
Complications
Unlike other posterior uveitides, which PIOL masquerades, if not detected and treated early, it may progress to CNS involvement with high fatality rates. The use of chemotherapeutic agents to treat the disease presents its own set of systemic and local complications such as pancytopenia, hepatic dysfunction, dry eye, cataract, and radiation retinopathy.
Deterrence and Patient Education
Patients diagnosed with primary intraocular lymphoma should be informed about the risk of central nervous system involvement and its symptoms such as behavioral change, new onset of seizures, hemiparesis, and ataxia.
Enhancing Healthcare Team Outcomes
Due to the high correlation between PIOL and PCNSL, collaboration with a neuro-oncologist, when available, enhances patient care. Baseline screening and periodic evaluation to look for PCNSL by neurologists help identify cases with high-risk mortality and early initiation of aggressive systemic chemotherapy. An ocular pathologist should be consulted before collecting any diagnostic specimens to help handle and process the specimen appropriately.
Media
(Click Image to Enlarge)
Figure 1: color fundus picture showing hazy vitreous media with multiple sub retinal yellow deposits and corresponding optical coherence tomography scan showing hyper reflective nodules in sub retinal space
Contributed by Simakurthy Sriram, MD
(Click Image to Enlarge)
Figure 2: Vitreous specimen collected in syringe and histopathological examination showing uniform population of small lymphocytes
Contributed by Sriram Simakurthy, MD
(Click Image to Enlarge)
Figure 3: Management of unilateral primary vitreoretinal lymphoma (PVRL) without central nervous system (CNS) involvement; MTX=methotrexate
Contributed by Soumya Jena
(Click Image to Enlarge)
Figure 4: Management of bilateral primary vitreoretinal lymphoma (PVRL)
Contributed by Soumya Jena
(Click Image to Enlarge)
Figure 5: Management of vitreoretinal lymphoma (VRL) with the involvement of central nervous system (CNS)
Contributed by Soumya Jena
References
Abrey LE,Ben-Porat L,Panageas KS,Yahalom J,Berkey B,Curran W,Schultz C,Leibel S,Nelson D,Mehta M,DeAngelis LM, Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Dec 20; [PubMed PMID: 17116938]
Level 2 (mid-level) evidenceCOOPER EL,RIKER JL, Malignant lymphoma of the uveal tract. American journal of ophthalmology. 1951 Aug; [PubMed PMID: 14857107]
Klingele TG,Hogan MJ, Ocular reticulum cell sarcoma. American journal of ophthalmology. 1975 Jan; [PubMed PMID: 1089097]
Mulay K,Narula R,Honavar SG, Primary vitreoretinal lymphoma. Indian journal of ophthalmology. 2015 Mar; [PubMed PMID: 25971162]
Raval V,Binkley E,Aronow ME,Valenzuela J,Peereboom DM,Singh AD, Primary central nervous system lymphoma - ocular variant: an interdisciplinary review on management. Survey of ophthalmology. 2021 Nov-Dec; [PubMed PMID: 33762182]
Level 3 (low-level) evidenceBuggage RR,Chan CC,Nussenblatt RB, Ocular manifestations of central nervous system lymphoma. Current opinion in oncology. 2001 May; [PubMed PMID: 11307054]
Level 3 (low-level) evidenceChan CC,Buggage RR,Nussenblatt RB, Intraocular lymphoma. Current opinion in ophthalmology. 2002 Dec; [PubMed PMID: 12441846]
Level 3 (low-level) evidenceCoupland SE,Foss HD,Hidayat AA,Cockerham GC,Hummel M,Stein H, Extranodal marginal zone B cell lymphomas of the uvea: an analysis of 13 cases. The Journal of pathology. 2002 Jul; [PubMed PMID: 12115879]
Level 3 (low-level) evidenceCoupland SE,Joussen A,Anastassiou G,Stein H, Diagnosis of a primary uveal extranodal marginal zone B-cell lymphoma by chorioretinal biopsy: case report. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2005 May; [PubMed PMID: 15586289]
Level 3 (low-level) evidenceChan CC,Shen D,Hackett JJ,Buggage RR,Tuaillon N, Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma. Ophthalmology. 2003 Feb; [PubMed PMID: 12578791]
Shannon-Lowe C,Rickinson AB,Bell AI, Epstein-Barr virus-associated lymphomas. Philosophical transactions of the Royal Society of London. Series B, Biological sciences. 2017 Oct 19 [PubMed PMID: 28893938]
Ongkosuwito JV,Van der Lelij A,Bruinenberg M,Wienesen-van Doorn M,Feron EJ,Hoyng CB,de Keizer RJ,Klok AM,Kijlstra A, Increased presence of Epstein-Barr virus DNA in ocular fluid samples from HIV negative immunocompromised patients with uveitis. The British journal of ophthalmology. 1998 Mar; [PubMed PMID: 9602620]
Level 2 (mid-level) evidenceShen DF,Herbort CP,Tuaillon N,Buggage RR,Egwuagu CE,Chan CC, Detection of Toxoplasma gondii DNA in primary intraocular B-cell lymphoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2001 Oct; [PubMed PMID: 11598169]
Level 3 (low-level) evidenceAhluwalia MS,Peereboom DM, Primary central nervous system lymphoma. Current treatment options in neurology. 2010 Jul; [PubMed PMID: 20842593]
Rivero ME,Kuppermann BD,Wiley CA,Garcia CR,Smith MD,Dreilinger A,Freeman WR, Acquired immunodeficiency syndrome-related intraocular B-cell lymphoma. Archives of ophthalmology (Chicago, Ill. : 1960). 1999 May; [PubMed PMID: 10326958]
Level 3 (low-level) evidenceGoldberg DE,Smithen LM,Angelilli A,Freeman WR, HIV-associated retinopathy in the HAART era. Retina (Philadelphia, Pa.). 2005 Jul-Aug; [PubMed PMID: 16077362]
Cassoux N,Merle-Beral H,Leblond V,Bodaghi B,Miléa D,Gerber S,Fardeau C,Reux I,Xuan KH,Chan CC,LeHoang P, Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocular immunology and inflammation. 2000 Dec; [PubMed PMID: 11262654]
Level 2 (mid-level) evidenceRajagopal R,Harbour JW, Diagnostic testing and treatment choices in primary vitreoretinal lymphoma. Retina (Philadelphia, Pa.). 2011 Mar; [PubMed PMID: 21336066]
Berenbom A,Davila RM,Lin HS,Harbour JW, Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy. Eye (London, England). 2007 Sep; [PubMed PMID: 16732210]
Level 2 (mid-level) evidenceChar DH,Ljung BM,Deschênes J,Miller TR, Intraocular lymphoma: immunological and cytological analysis. The British journal of ophthalmology. 1988 Dec; [PubMed PMID: 3067746]
Level 2 (mid-level) evidenceBhat PV,Jakobiec FA,Papaliodis G,Sobrin L, Primary T-cell lymphoma of the retina and cerebellum: immunophenotypic and gene rearrangement confirmation. American journal of ophthalmology. 2009 Sep; [PubMed PMID: 19477711]
Level 3 (low-level) evidenceCoupland SE,Loddenkemper C,Smith JR,Braziel RM,Charlotte F,Anagnostopoulos I,Stein H, Expression of immunoglobulin transcription factors in primary intraocular lymphoma and primary central nervous system lymphoma. Investigative ophthalmology [PubMed PMID: 16249468]
Level 2 (mid-level) evidenceGrimm SA,Pulido JS,Jahnke K,Schiff D,Hall AJ,Shenkier TN,Siegal T,Doolittle ND,Batchelor T,Herrlinger U,Neuwelt EA,Laperriere N,Chamberlain MC,Blay JY,Ferreri AJ,Omuro AM,Thiel E,Abrey LE, Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Annals of oncology : official journal of the European Society for Medical Oncology. 2007 Nov; [PubMed PMID: 17804469]
Level 2 (mid-level) evidenceHochberg FH,Miller DC, Primary central nervous system lymphoma. Journal of neurosurgery. 1988 Jun; [PubMed PMID: 3286832]
Sagoo MS,Mehta H,Swampillai AJ,Cohen VM,Amin SZ,Plowman PN,Lightman S, Primary intraocular lymphoma. Survey of ophthalmology. 2014 Sep-Oct; [PubMed PMID: 24560125]
Level 3 (low-level) evidenceAkpek EK,Ahmed I,Hochberg FH,Soheilian M,Dryja TP,Jakobiec FA,Foster CS, Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes. Ophthalmology. 1999 Sep; [PubMed PMID: 10485554]
Level 2 (mid-level) evidenceHoffman PM,McKelvie P,Hall AJ,Stawell RJ,Santamaria JD, Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes. Eye (London, England). 2003 May; [PubMed PMID: 12802353]
Level 2 (mid-level) evidenceChan CC,Rubenstein JL,Coupland SE,Davis JL,Harbour JW,Johnston PB,Cassoux N,Touitou V,Smith JR,Batchelor TT,Pulido JS, Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. The oncologist. 2011; [PubMed PMID: 22045784]
Level 3 (low-level) evidenceMarchese A,Miserocchi E,Giuffrè C,Cicinelli MV,Querques G,Bandello F,Modorati G, Aurora borealis and string of pearls in vitreoretinal lymphoma: patterns of vitreous haze. The British journal of ophthalmology. 2019 Nov; [PubMed PMID: 30709808]
Gass JD,Sever RJ,Grizzard WS,Clarkson JG,Blumenkranz M,Wind CA,Shugarman R, Multifocal pigment epithelial detachments by reticulum cell sarcoma. A characteristic funduscopic picture. Retina (Philadelphia, Pa.). 1984 Summer-Fall; [PubMed PMID: 6387833]
Level 3 (low-level) evidenceDean JM,Novak MA,Chan CC,Green WR, Tumor detachments of the retinal pigment epithelium in ocular/ central nervous system lymphoma. Retina (Philadelphia, Pa.). 1996; [PubMed PMID: 8927810]
Level 3 (low-level) evidenceFardeau C,Lee CP,Merle-Béral H,Cassoux N,Bodaghi B,Davi F,Lehoang P, Retinal fluorescein, indocyanine green angiography, and optic coherence tomography in non-Hodgkin primary intraocular lymphoma. American journal of ophthalmology. 2009 May; [PubMed PMID: 19243734]
Level 2 (mid-level) evidenceNoda S,Hayasaka S,Setogawa T, Intraocular lymphoma invades the optic nerve and orbit. Annals of ophthalmology. 1993 Jan; [PubMed PMID: 8427488]
Level 3 (low-level) evidenceGill MK,Jampol LM, Variations in the presentation of primary intraocular lymphoma: case reports and a review. Survey of ophthalmology. 2001 May-Jun; [PubMed PMID: 11425352]
Level 3 (low-level) evidenceBardenstein DS, Intraocular Lymphoma. Cancer control : journal of the Moffitt Cancer Center. 1998 Jul; [PubMed PMID: 10761081]
Forooghian F,Merkur AB,White VA,Shen D,Chan CC, High-definition optical coherence tomography features of primary vitreoretinal lymphoma. Ophthalmic surgery, lasers [PubMed PMID: 21956854]
Level 3 (low-level) evidenceVelez G,Chan CC,Csaky KG, Fluorescein angiographic findings in primary intraocular lymphoma. Retina (Philadelphia, Pa.). 2002 Feb; [PubMed PMID: 11884876]
Casady M,Faia L,Nazemzadeh M,Nussenblatt R,Chan CC,Sen HN, Fundus autofluorescence patterns in primary intraocular lymphoma. Retina (Philadelphia, Pa.). 2014 Feb; [PubMed PMID: 23958842]
Ursea R,Heinemann MH,Silverman RH,Deangelis LM,Daly SW,Coleman DJ, Ophthalmic, ultrasonographic findings in primary central nervous system lymphoma with ocular involvement. Retina (Philadelphia, Pa.). 1997; [PubMed PMID: 9143039]
Jack CR Jr,O'Neill BP,Banks PM,Reese DF, Central nervous system lymphoma: histologic types and CT appearance. Radiology. 1988 Apr; [PubMed PMID: 3279454]
Bessell EM,Hoang-Xuan K,Ferreri AJ,Reni M, Primary central nervous system lymphoma: biological aspects and controversies in management. European journal of cancer (Oxford, England : 1990). 2007 May; [PubMed PMID: 17433666]
Cheng G, Zhang J. Imaging features (CT, MRI, MRS, and PET/CT) of primary central nervous system lymphoma in immunocompetent patients. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2019 Mar:40(3):535-542. doi: 10.1007/s10072-018-3669-7. Epub 2018 Dec 22 [PubMed PMID: 30580380]
Hwang CS,Yeh S,Bergstrom CS, Diagnostic vitrectomy for primary intraocular lymphoma: when, why, how? International ophthalmology clinics. 2014 Spring; [PubMed PMID: 24613891]
Cursiefen C,Holbach LM,Lafaut B,Heimann K,Kirchner T,Naumann GO, Oculocerebral non-Hodgkin's lymphoma with uveal involvement: development of an epibulbar tumor after vitrectomy. Archives of ophthalmology (Chicago, Ill. : 1960). 2000 Oct; [PubMed PMID: 11030832]
Level 3 (low-level) evidenceCoupland SE,Bechrakis NE,Anastassiou G,Foerster AM,Heiligenhaus A,Pleyer U,Hummel M,Stein H, Evaluation of vitrectomy specimens and chorioretinal biopsies in the diagnosis of primary intraocular lymphoma in patients with Masquerade syndrome. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2003 Oct; [PubMed PMID: 14605902]
Level 2 (mid-level) evidenceTrudeau M,Shepherd FA,Blackstein ME,Gospodarowicz M,Fitzpatrick P,Moffatt KP, Intraocular lymphoma: report of three cases and review of the literature. American journal of clinical oncology. 1988 Apr; [PubMed PMID: 3282423]
Level 3 (low-level) evidenceWhitcup SM,Chan CC,Buggage RR,Nussenblatt RB,Byrnes GA,Rubin BI, Improving the diagnostic yield of vitrectomy for intraocular lymphoma. Archives of ophthalmology (Chicago, Ill. : 1960). 2000 Mar; [PubMed PMID: 10721983]
Level 3 (low-level) evidenceCoupland SE,Perez-Canto A,Hummel M,Stein H,Heimann H, Assessment of HOPE fixation in vitrectomy specimens in patients with chronic bilateral uveitis (masquerade syndrome). Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2005 Sep; [PubMed PMID: 15909161]
Nasir S,DeAngelis LM, Update on the management of primary CNS lymphoma. Oncology (Williston Park, N.Y.). 2000 Feb; [PubMed PMID: 10736810]
Wang Y,Shen D,Wang VM,Sen HN,Chan CC, Molecular biomarkers for the diagnosis of primary vitreoretinal lymphoma. International journal of molecular sciences. 2011; [PubMed PMID: 22016619]
Level 2 (mid-level) evidenceDavis JL,Miller DM,Ruiz P, Diagnostic testing of vitrectomy specimens. American journal of ophthalmology. 2005 Nov; [PubMed PMID: 16310459]
Level 2 (mid-level) evidenceFaia LJ,Chan CC, Primary intraocular lymphoma. Archives of pathology [PubMed PMID: 19653715]
Chan CC,Wallace DJ, Intraocular lymphoma: update on diagnosis and management. Cancer control : journal of the Moffitt Cancer Center. 2004 Sep-Oct; [PubMed PMID: 15377987]
Davis JL, Diagnosis of intraocular lymphoma. Ocular immunology and inflammation. 2004 Mar; [PubMed PMID: 15209459]
Benjamin D,Park CD,Sharma V, Human B cell interleukin 10. Leukemia [PubMed PMID: 8167552]
Sen HN,Bodaghi B,Hoang PL,Nussenblatt R, Primary intraocular lymphoma: diagnosis and differential diagnosis. Ocular immunology and inflammation. 2009 May-Jun; [PubMed PMID: 19585354]
Wolf LA,Reed GF,Buggage RR,Nussenblatt RB,Chan CC, Vitreous cytokine levels. Ophthalmology. 2003 Aug; [PubMed PMID: 12917196]
Level 3 (low-level) evidenceChan CC, Molecular pathology of primary intraocular lymphoma. Transactions of the American Ophthalmological Society. 2003; [PubMed PMID: 14971583]
Level 3 (low-level) evidenceDeAngelis LM, Brain tumors. The New England journal of medicine. 2001 Jan 11; [PubMed PMID: 11150363]
Frenkel S,Hendler K,Siegal T,Shalom E,Pe'er J, Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. The British journal of ophthalmology. 2008 Mar; [PubMed PMID: 18303160]
de Smet MD,Vancs VS,Kohler D,Solomon D,Chan CC, Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma. The British journal of ophthalmology. 1999 Apr; [PubMed PMID: 10434868]
Level 3 (low-level) evidenceJeong Y,Ryu JS,Park UC,Oh JY, Corneal Epithelial Toxicity after Intravitreal Methotrexate Injection for Vitreoretinal Lymphoma: Clinical and In Vitro Studies. Journal of clinical medicine. 2020 Aug 18; [PubMed PMID: 32824794]
Itty S,Pulido JS, Rituximab for intraocular lymphoma. Retina (Philadelphia, Pa.). 2009 Feb; [PubMed PMID: 19202422]
Larkin KL,Saboo US,Comer GM,Forooghian F,Mackensen F,Merrill P,Sen HN,Singh A,Essex RW,Lake S,Lim LL,Vasconcelos-Santos DV,Foster CS,Wilson DJ,Smith JR, Use of intravitreal rituximab for treatment of vitreoretinal lymphoma. The British journal of ophthalmology. 2014 Jan; [PubMed PMID: 24158837]
Level 2 (mid-level) evidenceHashida N,Ohguro N,Nishida K, Efficacy and Complications of Intravitreal Rituximab Injection for Treating Primary Vitreoretinal Lymphoma. Translational vision science [PubMed PMID: 24049708]
Rosenfeld MR,Pruitt AA, Management of malignant gliomas and primary CNS lymphoma: standard of care and future directions. Continuum (Minneapolis, Minn.). 2012 Apr; [PubMed PMID: 22810135]
Level 3 (low-level) evidenceDeAngelis LM, Primary central nervous system lymphomas. Current treatment options in oncology. 2001 Aug; [PubMed PMID: 12057111]
DeAngelis LM, Primary CNS lymphoma: treatment with combined chemotherapy and radiotherapy. Journal of neuro-oncology. 1999 Jul; [PubMed PMID: 10563431]
Soussain C,Merle-Béral H,Reux I,Sutton L,Fardeau C,Gerber S,Ben Othman T,Binet JL,Lehoang P,Leblond V, A single-center study of 11 patients with intraocular lymphoma treated with conventional chemotherapy followed by high-dose chemotherapy and autologous bone marrow transplantation in 5 cases. Leukemia [PubMed PMID: 9031115]
Level 3 (low-level) evidencePulido JS,Johnston PB,Nowakowski GS,Castellino A,Raja H, The diagnosis and treatment of primary vitreoretinal lymphoma: a review. International journal of retina and vitreous. 2018; [PubMed PMID: 29760948]
Mason JO,Fischer DH, Intrathecal chemotherapy for recurrent central nervous system intraocular lymphoma. Ophthalmology. 2003 Jun; [PubMed PMID: 12799254]
Level 3 (low-level) evidenceBaumann MA,Ritch PS,Hande KR,Williams GA,Topping TM,Anderson T, Treatment of intraocular lymphoma with high-dose Ara-C. Cancer. 1986 Apr 1; [PubMed PMID: 2418934]
Level 3 (low-level) evidenceStrauchen JA,Dalton J,Friedman AH, Chemotherapy in the management of intraocular lymphoma. Cancer. 1989 May 15 [PubMed PMID: 2702565]
Valluri S,Moorthy RS,Khan A,Rao NA, Combination treatment of intraocular lymphoma. Retina (Philadelphia, Pa.). 1995; [PubMed PMID: 7624599]
Level 3 (low-level) evidenceZhang Y,Zhou DB, Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment. Chinese medical journal. 2020 Jun 20; [PubMed PMID: 32452898]
Level 3 (low-level) evidenceSoussain C,Hoang-Xuan K,Taillandier L,Fourme E,Choquet S,Witz F,Casasnovas O,Dupriez B,Souleau B,Taksin AL,Gisselbrecht C,Jaccard A,Omuro A,Sanson M,Janvier M,Kolb B,Zini JM,Leblond V,Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire., Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 May 20; [PubMed PMID: 18413641]
Tun HW,Johnston PB,DeAngelis LM,Atherton PJ,Pederson LD,Koenig PA,Reeder CB,Omuro AMP,Schiff D,O'Neill B,Pulido J,Jaeckle KA,Grommes C,Witzig TE, Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood. 2018 Nov 22; [PubMed PMID: 30262659]
Soussain C,Choquet S,Blonski M,Leclercq D,Houillier C,Rezai K,Bijou F,Houot R,Boyle E,Gressin R,Nicolas-Virelizier E,Barrie M,Moluçon-Chabrot C,Lelez ML,Clavert A,Coisy S,Leruez S,Touitou V,Cassoux N,Daniau M,Ertault de la Bretonnière M,El Yamani A,Ghesquières H,Hoang-Xuan K, Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. European journal of cancer (Oxford, England : 1990). 2019 Aug; [PubMed PMID: 31279304]
Ahn IE,Jerussi T,Farooqui M,Tian X,Wiestner A,Gea-Banacloche J, Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood. 2016 Oct 13; [PubMed PMID: 27503501]
Ghesquieres H,Chevrier M,Laadhari M,Chinot O,Choquet S,Moluçon-Chabrot C,Beauchesne P,Gressin R,Morschhauser F,Schmitt A,Gyan E,Hoang-Xuan K,Nicolas-Virelizier E,Cassoux N,Touitou V,Le Garff-Tavernier M,Savignoni A,Turbiez I,Soumelis V,Houillier C,Soussain C, Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Apr 1; [PubMed PMID: 30698644]
Level 2 (mid-level) evidencePlowman PN,Montefiore DS,Lightman S, Multiagent chemotherapy in the salvage cure of ocular lymphoma relapsing after radiotherapy. Clinical oncology (Royal College of Radiologists (Great Britain)). 1993; [PubMed PMID: 8305342]
Level 3 (low-level) evidenceChar DH,Ljung BM,Miller T,Phillips T, Primary intraocular lymphoma (ocular reticulum cell sarcoma) diagnosis and management. Ophthalmology. 1988 May; [PubMed PMID: 3050698]
Grommes C,DeAngelis LM, Primary CNS Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jul 20; [PubMed PMID: 28640701]
Taoka K,Yamamoto G,Kaburaki T,Takahashi T,Araie M,Kurokawa M, Treatment of primary intraocular lymphoma with rituximab, high dose methotrexate, procarbazine, and vincristine chemotherapy, reduced whole-brain radiotherapy, and local ocular therapy. British journal of haematology. 2012 Apr; [PubMed PMID: 22085111]
Level 3 (low-level) evidenceChauhan K, Tripathy K. Pars Planitis. StatPearls. 2024 Jan:(): [PubMed PMID: 28613790]
Geetha R, Tripathy K. Chorioretinitis. StatPearls. 2024 Jan:(): [PubMed PMID: 31869169]
Simakurthy S, Tripathy K. Endophthalmitis. StatPearls. 2024 Jan:(): [PubMed PMID: 32644505]
Koundanya VV, Tripathy K. Syphilis Ocular Manifestations. StatPearls. 2024 Jan:(): [PubMed PMID: 32644383]
Gupta N, Tripathy K. Retinitis. StatPearls. 2024 Jan:(): [PubMed PMID: 32809355]
Bergstrom R, Tripathy K. Acute Retinal Necrosis. StatPearls. 2024 Jan:(): [PubMed PMID: 29262034]
Hormigo A,Abrey L,Heinemann MH,DeAngelis LM, Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. British journal of haematology. 2004 Jul; [PubMed PMID: 15238140]
Level 2 (mid-level) evidenceYang XL,Liu YB, Advances in Pathobiology of Primary Central Nervous System Lymphoma. Chinese medical journal. 2017 Aug 20; [PubMed PMID: 28776551]
Level 3 (low-level) evidencePlotkin SR,Batchelor TT, Primary nervous-system lymphoma. The Lancet. Oncology. 2001 Jun; [PubMed PMID: 11905752]
Jahnke K,Wagner T,Bechrakis NE,Willerding G,Coupland SE,Fischer L,Thiel E,Korfel A, Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2005 Dec; [PubMed PMID: 16219622]
Grimm SA,McCannel CA,Omuro AM,Ferreri AJ,Blay JY,Neuwelt EA,Siegal T,Batchelor T,Jahnke K,Shenkier TN,Hall AJ,Graus F,Herrlinger U,Schiff D,Raizer J,Rubenstein J,Laperriere N,Thiel E,Doolittle N,Iwamoto FM,Abrey LE, Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology. 2008 Oct 21; [PubMed PMID: 18936428]
Level 2 (mid-level) evidence